4//SEC Filing
CANCERVAX CORP 4
Accession 0001209191-05-032265
CIK 0001131907operating
Filed
Jun 15, 8:00 PM ET
Accepted
Jun 16, 2:18 PM ET
Size
5.7 KB
Accession
0001209191-05-032265
Insider Transaction Report
Form 4
CANCERVAX CORPCNVX
GAMMON GUY
Vice President, Clinical
Transactions
- Award
Stock Option (right to buy)
2005-06-14+25,000→ 25,000 totalExercise: $2.82From: 2005-06-14Exp: 2015-06-13→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]All shares vest immediately upon disclosure of the final results from the Canvaxin(TM) MMAIT-III Phase 3 clinical trial in patients with Stage III melanoma.
- [F2]Not applicable to this transaction.
Documents
Issuer
CANCERVAX CORP
CIK 0001131907
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001131907
Filing Metadata
- Form type
- 4
- Filed
- Jun 15, 8:00 PM ET
- Accepted
- Jun 16, 2:18 PM ET
- Size
- 5.7 KB